In the past week, HSDT stock has gone down by -38.68%, with a monthly decline of -92.83% and a quarterly plunge of -95.16%. The volatility ratio for the week is 19.45%, and the volatility levels for the last 30 days are 28.43% for Helius Medical Technologies Inc The simple moving average for the past 20 days is -83.30% for HSDT’s stock, with a -95.76% simple moving average for the past 200 days.
Is It Worth Investing in Helius Medical Technologies Inc (NASDAQ: HSDT) Right Now?
HSDT has 36-month beta value of 1.15. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for HSDT is 0.50M, and currently, short sellers hold a 12.41% ratio of that float. The average trading volume of HSDT on June 23, 2025 was 5.62M shares.
HSDT) stock’s latest price update
Helius Medical Technologies Inc (NASDAQ: HSDT)’s stock price has increased by 2705510 compared to its previous closing price of 0.33. However, the company has seen a -38.68% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-16 that – CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an additional authorized claim for payment for the PoNS Device from CignaHealth.
Analysts’ Opinion of HSDT
Many brokerage firms have already submitted their reports for HSDT stocks, with Noble Capital Markets repeating the rating for HSDT by listing it as a “Outperform.” The predicted price for HSDT in the upcoming period, according to Noble Capital Markets is $20 based on the research report published on March 24, 2021 of the previous year 2021.
HSDT Trading at -90.67% from the 50-Day Moving Average
After a stumble in the market that brought HSDT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.70% of loss for the given period.
Stock Fundamentals for HSDT
Current profitability levels for the company are sitting at:
- -33.41 for the present operating margin
- -0.34 for the gross margin
The net margin for Helius Medical Technologies Inc stands at -30.1. The total capital return value is set at -9.79. Equity return is now at value -800.00, with -282.74 for asset returns.
Currently, EBITDA for the company is -13.8 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of -2.17. The receivables turnover for the company is 0.86for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.69.
Conclusion
To put it simply, Helius Medical Technologies Inc (HSDT) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
